Prince Biotech, Inc. is a biotechnology company that researches and develops immunotherapy and regenerative medicine treatments based on Preimplantation Factor (PIF) and its synthetic analog, sPIF. The company focuses on addressing unmet medical needs in areas such as autoimmune diseases, traumatic brain injury, acute radiation syndrome, stroke, and reproductive medicine through diagnostic tests designed to improve IVF success rates.
Subscribe to see Prince Biotech, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Prince Biotech, Inc. is a biotechnology company headquartered in Mason, United States. Its most recent funding round raised $10M in October 2025. Xcout tracks 12 named people at Prince Biotech, Inc., including Douglas C. Prince, M.D. (Chief Executive Officer, board chair).
As of 16 November 2026. Source: Xcout Intel.
6 more named people on record for Prince Biotech, Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $10M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Prince Biotech, Inc.'s closest competitors — see the full list of competitors and alternatives →
Conception Holdings, Inc. develops stem cell technology and computational platforms to generate functional human eggs in the lab through in-vitro gametogenesis. The company aims to expand reproductive options for individuals facing biological and medical fertility limits by recreating key steps of human development.
Founded in 2020 and headquartered in Salt Lake City, Utah, Paterna Biosciences is a biotechnology research company focused on developing in vitro spermatogenesis technology to address male fertility and infertility challenges.
Eleven P15 Inc. is a biotechnology company focused on developing early-detection biomarkers and genetically-targeted therapeutics for idiopathic pulmonary fibrosis (IPF). The company aims to improve diagnosis and treatment outcomes for patients suffering from this fatal lung disease.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Epicrispr Biotechnologies is a pioneering therapeutics company dedicated to developing advanced genetic medicines. The organization focuses on scientific research, platforms, and clinical pipelines to treat serious diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Prince Biotech, Inc.? Suggest a correction · Work at Prince Biotech, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.